Clinical Research

Clinical Practice

Ruiz A, Daniels K, Barner J, Carson J, Frei C. Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study. BMC Women’s Health, 2011; 11(1).
Schwartz E, Holtorf K, Brownstein D. The Truth About Hormone Therapy. The Wall Street Journal, March 16, 2009: A17.
Klaiber E, Vogel W, Rako S.  A critique of the Women’s Health Initiative hormone therapy study. Fertility and Sterility, 2005; 84(6):1589-1601.

Menopause

Fait T.  Menopause hormone therapy: latest developments and clinical practice.  Drugs Context, 2019; 8:212551.
Thompson JJ, Ritenbaugh C, Nichter M.  Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.  BMC Womens Health, 2017;17(1):97.
Rech CM, Clapauch R, de Souza Md, Bouskela E.  Low testosterone levels are associated with endothelial dysfunction in oophorectomized early postmenopausal women.  Eur J Endocrinol, 2016; 174(3):297-306.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A.  Long term hormone therapy for perimenopausal and postmenopausal women.  Cochrane Database Syst Rev, 2012; (7):CD004143.
Ettinger B, Friedman G, Bush T, QusenberryJr C. Reduced Mortality Associated With Long-Term Postmenopausal Estrogen Therapy. Obstetrics & Gynecology, 1996; 87(1):6-12.

Cancer

Gordhandas S, Norquist BM, Pennington KP, et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol, 2019, pii: S0090-8258(18)31514-2.
Colditz G, Hankinson S, Hunter D, et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. The Endocrinologist, 1995; 5(6):441-442.

Sexual Function

Zilio Rech CM, Clapauch R, Bouskela E.  Sexual Function Under Adequate Estrogen Therapy in Women After Oophorectomy Versus Natural Menopause.  J Womens Health (Larchmt), 2019:  doi: 10.1089/jwh.2017.6905
Kushnir VA, Darmon SK, Barad DH, Weghofer A, Gleicher N.  Effects of dehydroepiandrosterone (DHEA) supplementation on sexual function in premenopausal infertile women.  Endocrine, 2018; doi: 10.1007/s12020-018-1781-3.
Labrie F, Archer D, Bouchard C, et al.  Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.  Climacteric, 2011; 14(2):282-288.

Mood Disorders

Sbisa A, van den Buuse M, Gogos A.  The effect of estrogenic compounds on psychosis-like behaviour in female rats.  PLoS One, 2018;13(3):e0193853.
Del Río JP, Alliende MI, Molina N et al. Steroid Hormones and Their Action in Women’s Brains: The Importance of Hormonal Balance.  Front Public Health, 2018; 6:141.
Kulkarni J.  Perimenopausal depression – an under-recognised entity. Aust Prescr, 2018; 41(6):183-185.
Ruiz AD, Daniels KR, Barner JC, Carson JJ, Frei CR.  Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study.  BMC Womens Health, 2011; 11:27.
Graziottin A, Serafini A.  Depression and the menopause: why antidepressants are not enough? Menopause Int, 2009; 15(2):76-81.

Infertility

Barad D, Gleicher N.  Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Human Reproduction, 2006; 21(11):2845-2849.

Barad D, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertility and Sterility, 2005; 84(3):756.e1-756.e3.

Metabolism and Obesity

Villareal D, Holloszy J. Effect of DHEA on Abdominal Fat and Insulin Action in Elderly Women and Men. JAMA, 2004; 292(18):2243.

Alzheimer’s Disease

Carroll JC, Rosario ER.  The potential use of hormone-based therapeutics for the treatment of Alzheimer’s disease.  Curr Alzheimer Res, 2012; 9(1):18-34.
Pike CJ, Carroll JC, Rosario ER, Barron AM.  Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol, 2009; 30(2):239-58.

Cardiovascular Disease

Schierbeck L, Rejnmark L, Tofteng C, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ,  2012; 345(9):e6409-e6409.
Nabel E. Coronary Heart Disease in Women — An Ounce of Prevention. New England Journal of Medicine, 2000; 343(8):572-574.

 Eye Disease

Anderson G.  Hormone Replacement Therapy May Protect Against Eye Disease. American Academy of Ophthalmology website. https://www.aao.org/newsroom/news-releases/detail/hormone-replacement-therapy-may-protect-against-ey. November 13, 2017. Accessed January 24, 2019.

Osteoporosis

Jankowski C, Gozansky W, Kittelson J, et al. Increases in Bone Mineral Density in Response to Oral Dehydroepiandrosterone Replacement in Older Adults Appear to Be Mediated by Serum Estrogens. The Journal of Clinical Endocrinology & Metabolism, 2008; 93(12):4767- 4773.

Migraine

Artero-Morales M, González-Rodríguez S, Ferrer-Montiel A.  TRP Channels as Potential Targets for Sex-Related Differences in Migraine Pain.  Front Mol Biosci, 2018; 5:73.

Lupus

Inflammatory Properties

Collomp K, Gravisse N, Vibarel-Rebot N.  Neuroendocrine and inflammatory responses to DHEA administration in young healthy women.  Pharmacol Biochem Behav, 2018;175:19-23.

Clinical Practice

Loria K. Polycythemia risk evaluated in patients on TRT pellets. Urology Times website. http://urologytimes.modernmedicine.com/urology-times/news/polycythemia-risk-evaluated-patients-trt-pellets?page=0,1. December 06, 2016. Accessed January 24, 2019.
Schwartz E, Holtorf K, Brownstein D. The Truth About Hormone Therapy. The Wall Street Journal, March 06, 2016:A17.
Morley J. The benefits and risks of testosterone replacement therapy: a review.  Therapeutics and Clinical Risk Management, 2009; 5:427-448.

Metabolic Syndrome

Rubinow KB. Estrogens and Body Weight Regulation in Men.  Adv Exp Med Biol, 2017; 1043:285-313.
Kelly D, Jones T. Testosterone: a metabolic hormone in health and disease. Journal of Endocrinology, 2013; 217(3):R25-R45.
Muraleedharan V, Hugh Jones T. Testosterone and the metabolic syndrome.  Ther Adv Endocrinol Metab, 2013; 1(5):207–223.

Diabetes

Haider A, Haider K, Saad F, Hanefeld M. Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report.  SAGE Open Med Case Rep, 2019; 7:2050313X18823454.

Magnussen LV, Hvid LG, Hermann AP, et al. Testosterone therapy preserves muscle strength and power in aging men with type 2 diabetes-a randomized controlled trial.  Andrology, 2017; 5(5):946-953.

Muraleedharan V, Marsh H, Kapoor D, Channer K, Jones T. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 2013; 169(6):725-733.

Mortality

Comhaire F. Hormone replacement therapy and longevity. Andrologia, 2015; 48(1): 65-68.
Shores M, Smith N, Forsberg C, Anawalt B, Matsumoto A.  Testosterone Treatment and Mortality in Men with Low Testosterone Levels. The Journal of Clinical Endocrinology & Metabolism, 2012; 97(6):2050-2058.
Laughlin G, Barrett-Connor E, Bergstrom J. Low Serum Testosterone and Mortality in Older Men. The Journal of Clinical Endocrinology & Metabolism, 2008; 93(1):68-75.

Cancer

Roddam A, Allen N, Appleby P, Key T. Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. Journal of the National Cancer Institute, 2008; 100(3):170-183.

DHEA

Villareal D, Holloszy J.  Effect of DHEA on Abdominal Fat and Insulin Action in Elderly Women and Men. JAMA, 2004; 292(18):2243.
Oberbeck R, Dahlweid M, Koch R, et al. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Critical Care Medicine, 2001; 29(2):380-384.
Wolkowitz O, Reus V, Keebler A, Nelson N, Friedland M. Double-Blind Treatment of Major Depression with Dehydroepiandrosterone. The American Journal of Psychiatry, 1999; 156(4):646-649.

Anti-Aging

Comhaire F.  Hormone replacement therapy and longevity.  Andrologia, 2016; 48(1):65-8.
Frederiksen L, Højlund K, Hougaard DM, Brixen K, Andersen M.  Testosterone therapy increased muscle mass and lipid oxidation in aging men.  Age (Dordr), 2012; 34(1):145-56.

Sexual Function

Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.  Eur Urol, 2017; 72(6):1000-1011.

Cardiovascular

Neuromuscular

Recovery Otzel DM, Lee J, Ye F, Borst SE, Yarrow JF.  Activity-Based Physical Rehabilitation with Adjuvant Testosterone to Promote Neuromuscular Recovery after Spinal Cord Injury.  Int J Mol Sci, 2018;19(6).

Hypogonadism

Sumii K, Miyake H, Enatsu N, Matsushita K, Fujisawa M.  Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy.  Andrologia, 2016; 48(2):198-202.

Alzheimer’s Disease

Pike CJ, Carroll JC, Rosario ER, Barron AM.  Protective actions of sex steroid hormones in Alzheimer’s disease.  Front Neuroendocrinol, 2009; 30(2):239-58.

Inflammation

Traish A, Bolanos J, Nair S, Saad F , Morgentaler A.  Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence.  J Clin Med, 2018; 7(12). pii: E549.

Sexual Function and Relationships

Kreuder AK, Wassermann L, Wollseifer M, et al. Oxytocin enhances the pain-relieving effects of social support in romantic couples.  Hum Brain Mapp, 2019; 40(1):242-251.
Scheele D, Wille A, Kendrick K, et al. Oxytocin enhances brain reward system responses in men viewing the face of their female partner. Proceedings of the National Academy of Sciences, 2013; 110(50):20308-20313.
Schneiderman I, Zagoory-Sharon O, Leckman JF, Feldman R.  Oxytocin during the initial stages of romantic attachment: relations to couples’ interactive reciprocity.  Psychoneuroendocrinology, 2012; 37(8):1277-85
Magon N, Sanjay K. The orgasmic history of oxytocin: Love, lust, and labor. Indian Journal of Endocrinology and Metabolism, 2011; 15(7):156.
Burri A, Heinrichs M, Schedlowski M, Kruger TH. The Acute effects of intranasal oxytocin administration on endocrine and sexual function in males. Psychoneuroendocrinology, 2008; 33(5):591-600.
Kiss A, Mikkelsen JD. Oxytocin–anatomy and functional assignments: a minireview. Endocr Regul, 2005; 39(3):97-105.
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev, 2001; 81(2):629-83.
Liedtke R. Hormone involved in reproduction may have role in the maintenance of relationships. BLTC Research. website.  https://www.oxytocin.org/oxytoc/index.html. July 14, 1999. Accessed Janurary 24, 2019.

Post Traumatic Stress Disorder

Flanagan JC, Hand A, Jarnecke AM, et al.  Effects of oxytocin on working memory and executive control system connectivity in posttraumatic stress disorder. Exp Clin Psychopharmacol, 2018; 26(4):391-402.
Olff M, Koch S, Nawijn L, et al. Social support, oxytocin, and PTSD.  European Journal of Psychotraumatology, 2014; 5:26513.

Mood Disorders

De Cagna F, Fusar-Poli L, Damiani S, et al. The Role of Intranasal Oxytocin in Anxiety and Depressive Disorders: A Systematic Review of Randomized Controlled Trials.  Clin Psychopharmacol Neurosci, 2019; 17(1):1-11.
Bertsch K, Herpertz SC.  Oxytocin and Borderline Personality Disorder.  Curr Top Behav Neurosci, 2018; 35:499-514.
Bosch OJ, Young LJ.  Oxytocin and Social Relationships: From Attachment to Bond Disruption.  Curr Top Behav Neurosci, 2018; 35:97-117.
Grace SA, Rossell SL, Heinrichs M, Kordsachia C, Labuschagne I.Oxytocin and brain activity in humans: A systematic review and coordinate-based meta-analysis of functional MRI studies.  Psychoneuroendocrinology, 2018; 96:6-24.
Kendrick KM, Guastella AJ, Becker B.  Overview of Human Oxytocin Research.  Curr Top Behav Neurosci, 2018; 35:321-348.
Jones C, Barrera I, Brothers S, Ring R, Wahlestedt C.  Oxytocin and social functioning.  Dialogues Clin Neurosci, 2017; 19(2):193-201.
Sippel LM, Allington CE, Pietrzak RH, et al. Oxytocin and Stress-related Disorders: Neurobiological Mechanisms and Treatment Opportunities.  Chronic Stress (Thousand Oaks), 2017;1.
Feeser M, Fan Y, Weigand A, et al. Oxytocin improves mentalizing – pronounced effects for individuals with attenuated ability to empathize.  Psychoneuroendocrinology, 2015; 53:223-32.
Herpertz S, Bertsch K. A New Perspective on the Pathophysiology of Borderline Personality Disorder: A Model of the Role of Oxytocin. American Journal of Psychiatry, 2015; 172(9), pp.840-851.
McQuaid R, McInnis O, Abizaid A, Anisman H. Making room for oxytocin in understanding depression. Neuroscience & Biobehavioral Reviews, 2014; 45, pp.305-322.
Bertsch K, Gamer M, Schmidt B, et al. Oxytocin and Reduction of Social Threat Hypersensitivity in Women With Borderline Personality Disorder. American Journal of Psychiatry, 2013; 170(10):1169-1177.
Domes G, Heinrichs M, Gläscher J, et al. Oxytocin Attenuates Amygdala Responses to Emotional Faces Regardless of Valence. Biological Psychiatry, 2007; 62(10):1187- 1190.

Weight Loss and Obesity

Ding C, Leow MK, Magkos F.  Oxytocin in metabolic homeostasis: implications for obesity and diabetes management.  Obes Rev, 2019; 20(1):22-40.
Spetter MS, Hallschmid M.  Current findings on the role of oxytocin in the regulation of food intake.  Physiol Behav, 2017; 176:31-39.
Olszewski PK, Klockars A, Levine AS.  Oxytocin and potential benefits for obesity treatment.  Curr Opin Endocrinol Diabetes Obes, 2017; 24(5):320-325.
Lawson EA.  The effects of oxytocin on eating behaviour and metabolism in humans.  Nat Rev Endocrinol, 2017; 13(12):700-709.
Altirriba J, Pataky Z, Golay A, Rohner-Jeanrenaud F. Oxytocin: metabolic effects and potential use for obesity treatment. Rev Med Suisse, 2015; 14(11):97-100.
Cai D, and Purkayastha S.  A new horizon: oxytocin as a novel therapeutic option for obesity and diabetes. Drug Discovery Today: Disease Mechanisms, 2013; 10(1-2):e63-e68.
Blevins J, Ho J.  Role of oxytocin signaling in the regulation of body weight. Rev Endocr Metab Disord, 2013; 14(4):311-329.

Autism

Auyeung B, Lombardo M, Heinrichs M, et al. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism. Translational Psychiatry, 2015; 5(2):507.
Li H, Shan L, Du L, Jay F.  Research advances in the management of autism spectrum disorders in children. Zhongguo Dang Dai Er Ke Za Zhi, 2015; 17(8):886-92.
Hollander E, Bartz J, Chaplin W, et al. Oxytocin Increases Retention of Social Cognition in AutismBiological Psychiatry, 2007; 61(4):498-503.

Addiction

Nielsen S, Gowing L, Sabioni P, Le Foll B.  Pharmacotherapies for cannabis dependence.  Cochrane Database Syst Rev, 2019; 1:CD008940.
Zhou L, Sun W, Young A, et al.  Oxytocin Reduces Cocaine Seeking and Reverses Chronic Cocaine-Induced Changes in Glutamate Receptor Function.  International Journal of Neuropsychopharmacology, 2014; 18(1):1093.
Rehme M, Hillemacher T, Heberlein A. Comment on “Intranasal Oxytocin Blocks Alcohol Withdrawal in Human Subjects” by Pedersen and Colleagues. Alcoholism: Clinical and Experimental Research, 2013; 37(5):720-721.
McGregor I, Bowen M.  Breaking the loop: Oxytocin as a potential treatment for drug addiction. Hormones and Behavior, 2012; 61(3):331-339.

Pediatric

Taylor A, Lee H, Buisman-Pijlman F. Oxytocin treatment in pediatric populations.  Frontiers in Behavioral. Neuroscience, 2014; 8:360.

Pain

Kreuder AK, Wassermann L, Wollseifer M, et al. Oxytocin enhances the pain-relieving effects of social support in romantic couples.  Hum Brain Mapp, 2019; 40(1):242-251.
Tracy L, Georgiou-Karistianis N, Gibson S, Giummarra M. Oxytocin and the modulation of pain experience: Implications for chronic pain management. Neuroscience & Biobehavioral Reviews, 2015; 55:53-67.
Rash J, Aguirre-Camacho A, Campbell T. Oxytocin and Pain. The Clinical Journal of Pain, 2013; 30:453-462.

Vaginal Atrophy

Kallak TK, Uvnäs-Moberg K.  Oxytocin stimulates cell proliferation in vaginal cell line Vk2E6E7.  Post Reprod Health, 2017; 23(1):6-12.
Al-Saqi SH, Jonasson AF, Naessén T, Uvnäs-Moberg K.  Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women.  Post Reprod Health, 2016; 22(1):25-33.
Al-Saqi SH, Uvnäs-Moberg K, Jonasson AF.  Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.  Post Reprod Health, 2015; 21(3):88-97.
Jonasson A, Edwall L, Uvnas-Moberg K. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause International, 2011; 17(4):120-125.

LDN Research Trust Low-Dose Naltrexone (LDN) 2017 Fact Sheet

Clinical Practice

Zagon IS, McLaughlin PJ.  Intermittent blockade of OGFr and treatment of autoimmune disorders.  Exp Biol Med (Maywood),2018:1535370218817746. doi: 10.1177/1535370218817746.
Toljan K, Vrooman B.  Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.  Med Sci (Basel), 2018;6(4).
Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol,2018;61:178-184.
Brown N, Panksepp J.  Low-dose naltrexone for disease prevention and quality of life.  Med Hypotheses, 2009; 72(3):333-337

Multiple Sclerosis

Ludwig MD, Zagon IS, McLaughlin PJ.  Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.  Exp Biol Med (Maywood), 2017; 242(15):1524-1533.
Ludwig MD, Turel AP, Zagon IS, Mc Laughlin PJ. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.  Mult Scler J Exp Transl Clin, 2016; 2:2055217316672242.
Turel AP, Oh KH, Zagon IS, McLaughlin PJ.  Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability.  J Clin Psychopharmacol, 2015; 35(5):609-611.
Frech T, Novak K, Revelo M, et al. Low-Dose Naltrexone for Pruritus in Systemic Sclerosis. International Journal of Rheumatology, 2011; 2011:1-5.
Cree BA, Kornyeyeva E, Goodin DS.  Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.  Ann Neurol, 2010; 68(2):145-150.
Zagon IS, Rahn KA, Turel AP, McLaughlin PJ.  Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.  Exp Biol Med (Maywood), 2009 ; 234(11):1383-1392.
Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis, 2008; 14(8):1076-1083.

Crohn’s Disease and Inflammatory Bowl Disease

Lie MRKL, van der Giessen J, Fuhler GM, et al.  Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.  J Transl Med, 2018; 16(1):55.
Roginsky G, Alexoff A, Ehrenpreis ED.  Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis.  J Clin Gastroenterol, 2015; 49(9):794-795.
Segal D, John K,  Macdonald J,  Nilesh C. Low Dose Naltrexone for Induction of Remission in   Crohn’s Disease. Cochrane Database of Systematic Reviews, 2014; (2):CD010410.
Smith J, Field D, Bingaman S, Evans R,  Mauger D.  Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease. Journal of Clinical Gastroenterology, 2013; 47(4):339-345.
Smith JP, Field D, Bingaman SI, Evans R, Mauger DT.  Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study.  J Clin Gastroenterol, 2013; 47(4):339-345.
Shannon A, Alkhouri N, Mayacy S, Kaplan B, Mahajan L.  Low-dose naltrexone for treatment of duodenal Crohn’s disease in a pediatric patient.  Inflamm Bowel Dis, 2010 Sep;16(9):1457.
Lichtenstein G, Hanauer S, Sandborn W. Management of Crohn’s Disease in Adults. Am J Gastroenterol, 2009; 104(2):465-483.
Smith J, Stock H, Bingaman S, et al. Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease. The American Journal of Gastroenterology, 2007; 102(4):820-828.

Autism

Woeller, K. Autism – The Benefits of Low Dose Naltrexone. Biomedical Autism Intervention. website. http://drkurtwoeller.blogspot.com/2009/01/autism-benefits-of-low-dose-naltrexone.html. January 09, 2009. Accessed January 24, 2019.
Bouvard M, Leboyer M, Launay J, et al.  Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Research, 1995; 58(3):191-201.
Ing B, Au D, Poland R. Low-Dose Naltrexone Inhibits Pemoline-Induced Self-Biting Behavior in Prepubertal Rats. Journal of Child and Adolescent Psychopharmacology, 1993; 3(2):71-79.
Campbell M, Anderson L, Small, A, et al. Naltrexone in Autistic Children: Behavioral Symptoms and Attentional Learning. Journal of the American Academy of Child & Adolescent Psychiatry, 1993; 32(6):1283-1291.
Sandman C. The Opiate Hypothesis in Autism and Self-Injury. Journal of Child and Adolescent Psychopharmacology, 1990; 1(3):237-248.
Campbell M, Overall J, Small A, et al. Naltrexone in Autistic Children: An Acute Open Dose Range Tolerance Trial. Journal of the American Academy of Child & Adolescent Psychiatry, 1989; 28(2):200-2006.

HIV/AIDS

Abdel T, Oumar T, Sounkalo D, et al.  Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: A single blind randomized clinical trial.  Journal of AIDS and HIV Research, 2011; 3(10):189-198.

Cancer

Miskoff JA, Chaudhri M. Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion.  Cureus, 2018; 10(7):e2924.
Meng J, Meng Y, Plotnikoff NP, et al. Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs).  Int Immunopharmacol, 2013; 17(4):1084-1089.
Donahue R, McLaughlin P, Zagon I. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Experimental Biology and Medicine, 2011; 236(7):883-895.

Fibromyalgia

Cote B, Ross B, Fortner J, Rao D.  The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia.  Int J Pharm Compd, 2018; 22(3):252-256.
Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low Dose Naltrexone in the Treatment of Fibromyalgia.  Curr Rheumatol Rev, 2018;14(2):177-180.
Ramanathan S, Panksepp J, Johnson B.  Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?  Psychosomatics,2012; 53(6):591-594.
Younger J, Mackey S. Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. Pain Med, 2009; 10(4):663-672.

Pain

Bostick, K, McCarter A, Nykamp D.  The Use of Low-Dose Naltrexone for Chronic Pain.  The Senior Care Pharmacist, 2019; 34(1):43-46.
Pineda-Farias JB, Caram-Salas NL, Salinas-Abarca AB, Ocampo J, Granados-Soto V. Ultra-Low Doses of Naltrexone Enhance the Antiallodynic Effect of Pregabalin or Gabapentin in Neuropathic Rats.  Drug Dev Res, 2017; 78(8):371-380.
Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A.  Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy.  Pain Med, 2016; 17(4):790-791.
Sturn KM, Collin M.  Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients.  Int J Pharm Compd, 2016; 20(3):197-201.
Ghai B, Bansal D, Hota D, Shah CS.  Off-label, low-dose naltrexone for refractory chronic low back pain.  Pain Med, 2014; 15(5):883-884.
Younger J, Parkitny L,  McLain D. The use of low-dose naltrexone (LDN) as a novel anti- inflammatory treatment for chronic pain. Clin Rheumatol, 2014; 33(4):451-459.
Chopra P, Cooper M.  Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN). Journal of Neuroimmune Pharmacology, 2013; 8(3):470-476.
Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.  J Pain, 2008; 9(8):700-713.

Addiction

Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA.  The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.  Am J Drug Alcohol Abuse, 2012;38(3):200-205.
Mannelli P, Patkar AA, Peindl K, et al.  Early outcomes following low dose naltrexone enhancement of opioid detoxification.  Am J Addict, 2009;18(2):109-116.
Webster LR.  Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.  Expert Opin Investig Drugs, 2007; (8):1277-83.
Postural Orthostatic Tachycardia Syndrome (POTS)
and Mast Cell Activation Syndrome (MCAS)

Mood Disorders

Pape W, Wöller W. Low dose naltrexone in the treatment of dissociative symptoms. Nervenarzt, 2015; 86(3):346-351.

Dermatology

Bridgman AC, Kirchhof MG.  Treatment of psoriasis vulgaris using low-dose naltrexone. JAAD Case Rep, 2018; 4(8):827-829.
Lee B, Elston D.  The Uses of Naltrexone in Dermatological Conditions.  J Am Acad Dermatol, 2018; (18)33104-9.
Ekelem C, Juhasz M, Khera P, Mesinkovska NA.  Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.   JAMA Dermatol, 2018; Doi:10.1001/jamadermatol.2018.4093.
Tran T, Chen A, Worswick S. Successful treatment of dermatomyositis with low-dose naltrexone.  Dermatol Ther, 2018; 31(6):e12720.
Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D.Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report.  Int J Pharm Compd, 2018; 22(4):270-278.
Atanaskova Mesinkovska N.  Emerging Unconventional Therapies for Alopecia Areata.  J Investig Dermatol Symp Proc, 2018;19(1):S32-S33.
Albers LN, Arbiser JL, Feldman RJ.Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone. JAMA Dermatol, 2017; 153(10):1018-1020.

Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease). JAMA Dermatol, 2017; 153(10):1015-1017.

Strazzulla LC, Avila L, Lo Sicco K, Shapiro J.  Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris.  J Drugs Dermatol, 2017;16(11):1140-1142.

Diabetes mellitus

McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS.  Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds.  Adv Wound Care (New Rochelle), 2017; 6(9):279-288.

Sassani JW, Mc Laughlin PJ, Zagon IS.  The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.  J Diabetes Res, 2016; 2016:9703729.
Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A.  Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy.  Pain Med, 2016; 17(4):790-791.
McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.  Brain Res Bull, 2010; 81(2-3):236-47.

Neurodegenerative diseases

Mischley LK, Conley KE, Shankland EG, et al.  Central nervous system uptake of intranasal glutathione in Parkinson’s disease.  NPJ Parkinsons Dis, 2016; 2:16002.
Saharan S, Mandal PK.  The emerging role of glutathione in Alzheimer’s disease.  J Alzheimers Dis, 2014; 40(3):519-29.
Cacciatore I, Baldassarre L, Fornasari E, Mollica A, Pinnen F.  Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems.  Oxid Med Cell Longev, 2012; 2012:240146.

Alternative Oral Formulations

Buonocore D, Grosini M, Giardina S, et al. Bioavailability Study of an Innovative Orobuccal Formulation of Glutathione.  Oxid Med Cell Longev, 2016; 2016:3286365.

Anti-aging properties

Homma T, Fujii J.  Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs.  Curr Drug Metab, 2015; 16(7):560-71.

Dermatological

Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P.  Glutathione and its antiaging and antimelanogenic effects.  Clin Cosmet Investig Dermatol, 2017; 10:147-153.

Immune Function

Sinha R, Sinha I, Calcagnotto A, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function.  Eur J Clin Nutr, 2018; 72(1):105-111.
Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.  Eur J Nutr, 2015; 54(2):251-63.
Kovacs-Nolan J, Rupa P, Matsui T, et al. In vitro and ex vivo uptake of glutathione (GSH) across the intestinal epithelium and fate of oral GSH after in vivo supplementation.  J Agric Food Chem, 2014; 62(39):9499-506.

Exercise

Aoi W, Ogaya Y, Takami M, et al.   Glutathione supplementation suppresses muscle fatigue induced by prolonged exercise via improved aerobic metabolism.  J Int Soc Sports Nutr, 2015; 12:7.

Autism

Kern J, Geier D, Adams J, Garver C, Audhya T, Geier M.  A clinical trial of glutathione supplementation in autism spectrum disorders. Med Sci Monit, 2011; 17(12): CR677–CR682.

Osteoporosis

Lean J, Davies J, Fuller K, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. Journal of Clinical Investigation, 2003; 112(6):915-923.

Antiviral Therapy

Fraternale A, Brundu S, Magnani M.  Glutathione and glutathione derivatives in immunotherapy.  Biol Chem,  2017; 398(2):261-275.
Fraternale A, Schiavano GF, Paoletti MF, et al. Effect of the N-butanoyl glutathione (GSH) derivative and acyclovir on HSV-1 replication and Th1 cytokine expression in human macrophages.  Med Microbiol Immunol, 2014; 203(4):283-9.
Borges-Santos MD, Moreto F, Pereira PC, Ming-Yu Y, Burini RC.  Plasma glutathione of HIV⁺ patients responded positively and differently to dietary supplementation with cysteine or glutamine. Nutrition, 2012; 28(7-8):753-6.
Fraternale A, Paoletti MF, Casabianca A, et al.  GSH and analogs in antiviral therapy.  Mol Aspects Med, 2009; 30(1-2):99-110.
Fraternale A, Paoletti M, Casabianca A, et al. Inhibition of murine AIDS by pro-glutathione (GSH) molecules. Antiviral Research, 2008;  77(2):120-127.
Palamara AT, Brandi G, Rossi L, et al.  New synthetic glutathione derivatives with increased antiviral activities.  Antivir Chem Chemother, 2004; 15(2):83-91.
Vogel J, Cinatl J, Dauletbaev N, et al. Effects of S-acetylglutathione in cell and animal model of herpes simplex virus type 1 infection. Med Microbiol Immunol, 2003; 194(1-2):55-59.

Cancer

Balendiran GK, Dabur R, Fraser D.  The role of glutathione in cancer.  Cell Biochem Funct, 2004; 22(6):343-52.
Locigno R, Pincemail J, Henno A, Treusch G, Castronovo V.  S-acetyl-glutathione selectively induces apoptosis in human lymphoma cells through a GSH-independent mechanism. Int J Oncol, 2002; 20(1):6975.

Pharmacokinetics and Pharmacodynamics

Blanchemain N, Siepmann F, Siepmann J. Implants for drug substance delivery. Med Sci (Paris), 2017; 33(1):32-38.
McFarland J, Craig W, Clarke NJ, Spratt DI.  Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone.  J Endocr Soc, 2017;1(8):1095-1103.
Glaser R, Kalantaridou S, Dimitrakakis C.  Testosterone implants in women: pharmacological dosing for physiologic effect. Maturitas, 2013; 74(2):179-84.
Pastuszak A, Mittakanti H, Liu J, et al. Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets. Journal of Andrology, 2012; 33(5):927-937.
Kelleher S, Howe C, Conway AJ, Handelsman DJ.  Testosterone release rate and duration of action of testosterone pellet implants.  Clin Endocrinol (Oxf), 2004; 60(4):420-8.
Cravioto M, Larrea F, Delgado N, et al. Pharmacokinetics and pharmacodynamics of 25-mg estradiol implants in postmenopausal Mexican women. Menopause, 2001; 8(5):353-360.

Patient Adherence and Satisfaction

Piecuch MJ, Patel BG, Hakim L, Wang R, Sadeghi-Nejad H.  Testosterone Pellet Implantation Practices: A Sexual Medicine Society of North America (SMSNA) Member Questionnaire.  J Sex Med, 2017; 14(1):47-49.
Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, Spratt LV, Eimicke T, Olshan JS.  Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients.  J Clin Endocrinol Metab, 2017; 102(7):2349-2355.
Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI.  Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen.  Sex Med, 2015; 3(3):165-73.
Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI. Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.  J Sex Med, 2014; 11(2):553-62.
McCullough A. A Review of Testosterone Pellets in the Treatment of Hypogonadism.  Curr Sex Health Rep, 2014;6(4):265-269.
Smith RP, Khanna A, Coward RM, Rajanahally S, Kovac JR, Gonzales MA, Lipshultz LI.  Factors influencing patient decisions to initiate and discontinue subcutaneous testosteronepellets 
(Testopel) for treatment of hypogonadism. J Sex Med, 2013;10(9):2326-33.

Menopause

Britto R, Araújo L, Barbosa I, Silva L.  Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants. Gynecological Endocrinology, 2012; 28(10):767-769.
Studd J, Savvas M, Waston N, et al. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. American Journal of Obstetrics and Gynecology, 1990; 163(5):1474-1479.
Stanczyk F, Shoupe D, Nunez V, et al. A randomized comparison of nonoral estradiol delivery in postmenopausal women.  American Journal of Obstetrics and Gynecology, 1988; 159(6):1540-1546.
Greenblatt R, Bryner J, Mahesh V, Asch R. Implantation of pure crystalline pellets of estradiol for conception control. Am J Obstet Gynecol, 1977; 127(5):520-524.

Breast Cancer

Glaser RL, York AE, Dimitrakakis C. Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors. J Clin Oncol 2014; 32 Suppl 2:109.

Migraine

Glaser R, Dimitrakakis C, Trimble N, Martin V.  Testosterone pellet implants and migraine headaches: a pilot study.  Maturitas, 2012; 71(4):385-8.

Contact Belmar Pharma Solutions

Learn More

If you’re a patient, we’re here to help you fill prescriptions or provide you the information you need to work with your doctor to help decide if a compounded prescription might be a good treatment for you.

Prescribers, for a complete formulary or access to our clinical resources fill out the form below and one of our Solutions Engineers will be in touch shortly. If you are new to compounding, you may also find our page on How to Write a Compounding Prescription helpful.


PatientPhysician
Please choose one.









Thank you for reaching out. A member of our team is reviewing your message and will reach out as soon as possible. In the meantime, below are a few links, including our formulary, that we think you might find helpful:

Formulary
Conditions
Patient Blog

Thank you for reaching out. A member of our team is reviewing your message and will reach out as soon as possible. In the meantime, below are a few links, including our formulary, that we think you might find helpful:

Formulary
Treatment Options
Clinician Blog
Download our HIPAA Form

Belmar Pharma Solutions adheres to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and we promise to keep your health information secure and private. Download and follow the instructions on this form to acknowledge that you have received this notification.